Caris Life Sciences (CAI) return on equity (ROE)
Only 1 fiscal year of return on equity is on record here for Caris Life Sciences (CAI); a history needs at least 3. Figures as of 17 Nov 2026, 23:10 UTC, from Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- -11.8%
- Fiscal years on record
- 12025–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Not enough data
A history of return on equity needs at least 3 fiscal years; one is on record here for Caris Life Sciences. Nothing is estimated to fill the gap. What is on record is in the table below.
Caris Life Sciences return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | -11.8% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| Cytokinetics CYTK | -88.3% | 2021 |
| ABIVAX ABVX | -73.8% | 2025 |
| Bausch + Lomb BLCO | -5.6% | 2025 |
| Amneal Pharmaceuticals AMRX | -424.6% | 2023 |
| Caris Life Sciences CAI | -11.8% | 2025 |
| Immunovant IMVT | -59.3% | 2026 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Caris Life Sciences, figure by figure
- Caris Life Sciences market cap
- Caris Life Sciences revenue
- Caris Life Sciences earnings
- Caris Life Sciences earnings per share (EPS)
- Caris Life Sciences P/E ratio
- Caris Life Sciences P/S ratio
- Caris Life Sciences P/B ratio
- Caris Life Sciences free cash flow
- Caris Life Sciences operating margin
- Caris Life Sciences dividend
- Caris Life Sciences shares outstanding
- Caris Life Sciences total debt
- Caris Life Sciences cash on hand
- Caris Life Sciences total assets
- Caris Life Sciences return on invested capital (ROIC)
Caris Life Sciences (CAI) overview: price, valuation and scorecardAll health care companies by market value
Caris Life Sciences return on equity (ROE): questions and answers
How is Caris Life Sciences's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Caris Life Sciences (CAI) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/CAI/roe
Underlying data: Yahoo Finance.